Alopecia areata is a disorder in which the body reacts against itself, an 'auto immune disorder', causing patches of hair to fall out. It can start at any age but is most likely to start in childhood.

Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

Medically reviewed by Susan Bard, MD Alopecia areata is a common hair loss condition. It affects people of all ages, races, ...

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

Retail investor interest in Q32 Bio Inc picked up on Wednesday after the clinical-stage biotech said the U.S. Food and Drug ...

Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage trial.

Alopecia areata affects 8.3 million people globally, significantly impacting quality of life. PROMs are essential for integrating patient perspectives into drug development and evaluating ...

Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...

Masumi Tsunoda, a 45-year-old woman in Maebashi, Gunma Prefecture, who is an alopecia areata patient, was asked to design a headscarf for Licca-chan. Tsunoda contracted the disease 10 years ago.

has granted Fast Track designation to bempikibart for the treatment of Alopecia Areata (AA), an autoimmune disease that attacks hair follicles causing patchy hair loss. Fast Track is a process ...

My daughter 10-year-old daughter suffers from alopecia. It started suddenly after her father died. But now, after five months, it is still not growing back. She hasn't lost any more hair but she ...